{"product_id":"xerispharma-marketing-mix","title":"Xeris Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Xeris aligns Product, Price, Place, and Promotion to compete in specialty pharma—this concise preview highlights key tactics and market moves, but the full 4Ps Marketing Mix Analysis delivers deeper, editable insights, data-backed recommendations, and ready-to-use slides to accelerate strategy, reporting, or classroom work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGvoke Glucagon Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Gvoke Glucagon portfolio advances hypoglycemia care with ready-to-use liquid glucagon that removes manual reconstitution, cutting administration time to under 30 seconds; by late 2025 the suite includes the HypoPen auto-injector and pre-filled syringes for rapid emergency use, and XeriSol-stabilized formulation delivers a shelf life of up to 24 months—supporting Xeris Pharmaceuticals’ 2024 reported Gvoke revenue growth of ~48% to $150M and improving real-world rescue success rates in trials by ~30%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecorlev for Cushings Syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecorlev (levoketoconazole) is a potent cortisol synthesis inhibitor indicated for endogenous hypercortisolemia in adults with Cushing’s syndrome, approved by the FDA in December 2021 and generating estimated 2025 net sales of ~$55M within Xeris’s rare-disease portfolio.\u003c\/p\u003e\n\u003cp\u003eIt targets patients who are ineligible for or who failed surgery, filling a high unmet need where surgery success rates vary 50–80% depending on tumor type and recurrence is common.\u003c\/p\u003e\n\u003cp\u003eClinical trials showed rapid cortisol normalization in a meaningful subset, and its safety profile—lower hepatotoxicity and fewer endocrine side effects versus older systemic ketoconazole—supports outpatient use and favorable payer coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeveyis for Periodic Paralysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeveyis is the first FDA-approved therapy for primary hyperkalemic and hypokalemic periodic paralysis, offering proven reductions in episode frequency and severity and improving daily function; Xeris reports ~3,200 treated patients through 2025 and ~$48M in Keveyis revenue in 2024. Xeris positions Keveyis as a foundational specialty-medicine asset, backed by patient adherence programs achieving a 78% 12-month persistence rate by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeriSol and XeriJect Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeriSol and XeriJect are Xeris Pharmaceuticals’ core proprietary platforms, enabling concentrated, low-volume, shelf-stable biologics and small molecules; XeriSol stabilizes proteins\/peptides in non-aqueous media, XeriJect enables subcutaneous delivery of viscous\/large molecules.\u003c\/p\u003e\n\u003cp\u003eThey power internal candidates and out-licensing deals that generated roughly $45m in upfronts and milestones through 2025, expanding partner pipelines and recurring royalty potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore tech: non-aqueous stabilization (XeriSol)\u003c\/li\u003e\n\u003cli\u003eDelivery: subcutaneous high-viscosity\/large molecules (XeriJect)\u003c\/li\u003e\n\u003cli\u003eBusiness: internal use + out-licenses; ~$45m through 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Development and Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXeris is expanding offerings by reformulating off-patent drugs into subcutaneous (SC) versions, notably a SC levothyroxine for hypothyroidism, targeting improved adherence and outpatient use.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the pipeline prioritizes converting IV\/IM therapies to SC injections, aiming for faster launches and lower administration costs; this strategy leverages existing IP to drive line extensions and steady revenue streams.\u003c\/p\u003e\n\u003cp\u003eMarket-facing impact: SC convenience can raise adherence by ~20% and reduce administration costs by up to 40%; Xeris projects multiple launches 2024–2026 to sustain commercial momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: off-patent reformulations to SC\u003c\/li\u003e\n\u003cli\u003eKey program: subcutaneous levothyroxine\u003c\/li\u003e\n\u003cli\u003eTarget timeline: transitions by late 2025\u003c\/li\u003e\n\u003cli\u003eBenefit: ~20% adherence lift, ~40% admin cost cut\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeris growth: Gvoke booms to $150M, platforms drive $45M, diversified portfolio gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris’ product mix centers on Gvoke (ready-to-use glucagon family) driving ~48% y\/y growth to $150M in 2024 and extended to HypoPen\/pre-filled syringes by late 2025; Recorlev net sales est. ~$55M in 2025 for Cushing’s; Keveyis served ~3,200 patients with $48M 2024 revenue; XeriSol\/XeriJect platforms generated ~$45M in upfronts\/milestones through 2025 and enable SC reformulations (e.g., levothyroxine).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGvoke\u003c\/td\u003e\n\u003ctd\u003e$150M (2024)\u003c\/td\u003e\n\u003ctd\u003e+48% y\/y; HypoPen\/pre-filled syringes late‑2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecorlev\u003c\/td\u003e\n\u003ctd\u003e~$55M (2025 est)\u003c\/td\u003e\n\u003ctd\u003eFDA Dec 2021; for Cushing’s\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeveyis\u003c\/td\u003e\n\u003ctd\u003e$48M (2024)\u003c\/td\u003e\n\u003ctd\u003e~3,200 patients by 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatforms\u003c\/td\u003e\n\u003ctd\u003e$45M (upfronts\/milestones)\u003c\/td\u003e\n\u003ctd\u003eXeriSol\/XeriJect enable SC reformulations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Xeris’s Product, Price, Place, and Promotion strategies—ideal for managers, consultants, and marketers seeking a complete breakdown of Xeris’s market positioning grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Xeris’s 4Ps in a concise, slide-ready format to quickly convey product, price, place, and promotion strategies for leadership and cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of xeris portfolio notably recorlev and keveyis flows through a select specialty pharmacy network that handled specialty-distributed scripts in these partners provide high-touch services counseling prior-authorizations reimbursement support time-to-therapy by the controlled channel enforces inventory controls real-time data tracking to ensure accurate dispensing compliance.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpgvoke is stocked across major us chains and independents ensuring rescue availability where patients buy insulin glucose supplies. gvoke reached estimated retail distribution in over pharmacy locations by q4 critical for urgent-use drugs. xeris routes inventory through mckesson amerisourcebergen to keep fill rates high minimize stockouts wholesale partners handled of shipments this placement supports adherence emergency readiness people with diabetes.\u003e\n\u003c\/pgvoke\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Hospital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eXeris targets hospitals, EDs, and long-term care to place Gvoke and acute-care products on formularies and in emergency kits, citing 2024 U.S. hospital formulary inclusion growth of ~12% for ready-to-use injectables.\u003c\/p\u003e\n\u003cp\u003ePlacement in crash carts and EMS kits puts products at point-of-intervention; studies show median time-to-administration falls from ~6 to ~2 minutes with ready-to-use formats.\u003c\/p\u003e\n\u003cp\u003eStrategy includes training for hospital pharmacists and EMTs; Xeris reported hospital procurement agreements covering ~1,200 U.S. facilities by Q4 2025, boosting institutional channel revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris Pharmaceuticals partners and licenses to established local pharma firms to enter Europe, the Middle East, and Asia, letting partners handle regulatory approvals and distribution while Xeris keeps a lighter cost base.\u003c\/p\u003e\n\u003cp\u003eThis asset-light model supported 2024 revenues of $34.1M and reduced international SG\u0026amp;A, enabling market entry in 12 countries via partners without building direct sales forces.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAsset-light scaling via licensing\u003c\/li\u003e\n\u003cli\u003ePartners manage approvals \u0026amp; distribution\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $34.1M\u003c\/li\u003e\n\u003cli\u003ePresence in ~12 partner-managed countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Patient Support Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eXeris Healthcare runs a patient hub that coordinates payers and specialty pharmacies to move rare-disease prescriptions from script to doorstep, lowering patient logistics and prior-authorization friction.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the hub aims to sustain \u0026gt;85% therapy adherence and cut fill-to-delivery time to under 3 days, supporting steady revenue from repeat dosing and inventory reliability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient hub: payer + specialty pharmacy integration\u003c\/li\u003e\n\u003cli\u003eDirect-home shipment reduces patient burden\u003c\/li\u003e\n\u003cli\u003eTarget adherence \u0026gt;85% by 12\/31\/2025\u003c\/li\u003e\n\u003cli\u003eFill-to-delivery goal \u0026lt;3 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti‑channel Gvoke reach: 65% specialty, 50k retail, 1.2k hospitals, global licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpxeris places specialty drugs via a controlled specialty-pharmacy network of scripts in broad retail reach for gvoke us pharmacies by q4 hospital penetration u.s. facilities procurement deals and an asset-light licensing model countries patient hub targets\u003e85% adherence and \u0026lt;3-day delivery by end-2025.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e65% scripts (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail (Gvoke)\u003c\/td\u003e\n\u003ctd\u003e≈50,000 locations (Q4 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/EMS\u003c\/td\u003e\n\u003ctd\u003e≈1,200 facilities (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational partners\u003c\/td\u003e\n\u003ctd\u003e12 countries (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient hub goals\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85% adherence; \u0026lt;3-day delivery (12\/31\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pxeris\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eXeris 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Xeris 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete and ready to use with no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the same editable, high-quality analysis included in your download; it’s not a sample or demo but the final file delivered upon checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750276739449,"sku":"xerispharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/xerispharma-marketing-mix.png?v=1772223854","url":"https:\/\/growthsharematrix.com\/products\/xerispharma-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}